¿´Æ¬ÊÓƵ

Object moved to here.

¿´Æ¬ÊÓƵ :: Pilot & Feasibility Program Application

¿´Æ¬ÊÓƵ


HP-MRI organ imaging to identify the risk of DKA with SGLT2 inhibitors in DM
Summary Data Summary
Applicant Shabbir, Waheed
E-Mail Address waheed.shabbir@ucsf.edu
Project Title HP-MRI organ imaging to identify the risk of DKA with SGLT2 inhibitors in DM
CBU ID 20AU4156
External SubContract ID 32307-83
Diabetic Complication All Complications
Funding Program Group Pilot & Feasibility [PF2020]
Abstract SGLT2 inhibitors are important antidiabetic drugs with a broad range of effects.
Many studies including the FDA warned that the use of SGLT2 inhibitors can
increase the risk of diabetic ketoacidosis. The number of DKA incidence
increased markedly worldwide, with one estimate suggesting that as many as
145,000 cases/year with T1DM in North America. T1DM patients are more likely to
develop SGLT2 inhibitors associated with DKA due to insulin deficiency, which
are amongst the most common causes of DKA. Indeed, it has been shown that the
incidence of DKA in individuals with T1DM is higher than T2DM who are exposed to
SGLT2 inhibitors. To date, no medical commodity available for non-invasive
imaging of DKA. Therefore, a non-invasive real-time tissue interrogation
technique is critically needed. To fill this gap, we have developed a
non-invasive real-time HP-MRI organ imaging technique. Indeed, using HP-MRI we
have detected divergent metabolic differences in gluconeogenic tissue between
models of T1 and T2DM. In this project, our laboratory is interested in studying
whether we can image the DKA non-invasively in vivo, in DM models. Using two
contrasting DM rat models we are particularly interested to answer the following
questions: (1) Whether we can image the ketone body turnover in kidney and in
the liver following SGLT2 inhibitors treatment in real-time in vivo. (2) Whether
the kidneys and livers of animals treated with SGLT2 inhibitors show increased
ketone body turnover; and (3) Whether SGLT2-mediated gluconeogenesis signals go
hand in hand with ketogenesis
Application PDF Application Research Plan
Status Contract Executed
Key Personnel David Pearce, MD, Principal Investigator
Waheed Shabbir, PhD, Co-Investigator
Michael Ohliger, MD, PhD
Cornelius von Morze, PhD
Enzo Takagi
Salary Total Costs 47096
Supply Total Costs 12848
Equipment Total Costs 0
Travel/Other Total Costs 1975
Direct Costs 61919
Indirect Costs Proposed 38080
Total Costs Proposed 99999
Total Costs Approved 99999
Start Date 11/1/2020
End Date 10/31/2021
IFO Name McCaffrey, Ellyn
IFO E-Mail Address Ellyn.McCaffrey@ucsf.edu
IACUC/IRB No. ANI73478-03
IACUC/IRB Institution University of California-San Francisco
Entity ID No. 94-6036493
Report Request Date 10/31/2021
T1D NO
TypeCount
Invoices 8
Progress Reports 1
Data Submission


Invoices
UrlCBU IDExternal IDInstitutionDateDirectIndirectInvoiceBalancePDF
  View  20AU415632307-83University of California-San Francisco9/13/2021$2,978.59$1,831.85$4,810.44$778.77View PDF
  View  20AU415632307-83University of California-San Francisco8/23/2021$19,062.47$11,723.43$30,785.90$778.77View PDF
  View  20AU415632307-83University of California-San Francisco6/16/2021$9,656.56$5,938.79$15,595.35$778.77View PDF
  View  20AU415632307-83University of California-San Francisco5/12/2021$6,505.59$4,000.91$10,506.50$778.77View PDF
  View  20AU415632307-83University of California-San Francisco4/15/2021$18,239.40$11,217.21$29,456.61$778.77View PDF
  View  20AU415632307-83University of California-San Francisco12/15/2021$2,700.43$1,660.76$4,361.19$778.77View PDF
  View  20AU415632307-83University of California-San Francisco10/18/2021$2,156.58$1,326.27$3,482.85$778.77View PDF
  View  20AU415632307-83University of California-San Francisco1/18/2022-$221.39$221.39$778.77View PDF


Reports
Click here to cancel and return to funding program application

*Author:
*SubContract:
*Select File:

Click browse and select the file to upload.
(Please upload ONLY TXT, Image Files (not histolgy), PDF, XLS, XLSX, DOC, or DOCX files.)